BioWorld

April 29, 2002

FDA Nixes Cellegy Pain Drug; Stock Takes Half-Off Nosedive

Cellegy Pharmaceuticals Inc.’s stock tumbled more than 50 percent on news that the company is withdrawing the new drug application for Cellegesic, its nitroglycerin ointment for the treatment of pain from anal fissures. (BioWorld Today) Read More

Senators Want To Close Gaps In Generic Drug Legislation

Hirschsprung Disease Gene Find Is First Complete Dissection Of Multifactorial Genetic Disorder

IDEC, Seikagaku Add $34M Extension To IDEC-152 Deal

Other News To Note

BIO Names Specter, Harkin Top Legislators Of The Year

Appointments And Advancements

Quarterly Earnings Reports

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles

mRNA flu vaccine can activate broad germinal center response

BioWorld

On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...